Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polyvalent pneumococcus and B-type haemophilus influenzae combined vaccine

A technology for Haemophilus influenzae and pneumococcus, which can be used in multivalent vaccines, vaccines, antibacterial drugs, etc., can solve the problems of high sensitivity of infectious pathogens, inability to play a role, and difficult to promote, and achieves elimination of allergens and easy solubility. Good and easy vaccine transport effect

Pending Publication Date: 2016-11-09
BRAVOVAX
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Others, such as molecular biology detection techniques, have higher sensitivity for detecting infectious pathogens, and this kind of test is expensive, so it is difficult to promote in economically backward areas
Therefore, prevention before the patient is infected is a good countermeasure.
[0005] 2. Limitations of Existing Technology
Immunization adjuvants fail to work if not used with appropriate vaccine, study finds

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polyvalent pneumococcus and B-type haemophilus influenzae combined vaccine
  • Polyvalent pneumococcus and B-type haemophilus influenzae combined vaccine
  • Polyvalent pneumococcus and B-type haemophilus influenzae combined vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-1

[0064] 1. Preparation of Haemophilus influenzae type B capsular saccharide

[0065] 1. Use CY medium to ferment the Hib strain at 37°C, inactivate the fermentation broth with formaldehyde, centrifuge to get the supernatant, and use cetyltrimethylammonium bromide (CTAB) for precipitation. Then use 0.5-1M NaCl to dissociate the complex precipitation, add glacial ethanol to a final concentration of 25% (v / v) to precipitate nucleic acid, then add glacial ethanol to a final concentration of 75% (v / v), and precipitate to obtain rough sugar .

[0066] 2. The above crude sugar was dissolved in sodium acetate solution, extracted 5-6 times with cold phenol, and finally concentrated by ultrafiltration to remove phenol residue, and refined sugar was obtained by 75% (v / v) ethanol precipitation, and stored at -20°C for later use.

[0067] 2. Preparation of pneumococcal polysaccharide

[0068] 1. Select seven serotypes (4, 6B, 9V, 14, 18C, 19F, 23F) of pneumococci for culture;

[0069]2. ...

Embodiment 1-2

[0086] The only difference between this example and Example 1-1 is that the order of adding polysaccharides in this example is to add pneumococcal capsular saccharide and Haemophilus influenzae type B capsular saccharide at the same time. There is no chromatographic peak of Haemophilus influenzae type B capsular saccharide after the order is changed, which proves that adding pneumococcal capsular saccharide and Haemophilus influenzae type B capsular saccharide at the same time according to the original ratio will form a competitive relationship and affect the pod of Haemophilus influenzae type B. The normal conjugation process of membrane sugars, so the technical solution cannot be realized.

Embodiment 1-3

[0088] The only difference between this example and Example 1-1 is that the order of adding polysaccharides in this example is to add the capsular saccharide of pneumococcus first, and then add the capsular saccharide of Haemophilus influenzae type b. There is no chromatographic peak of capsular saccharide of Haemophilus influenzae type B after the order is changed, which proves that the addition of capsular saccharide of pneumococcus first and the capsular saccharide of Haemophilus influenzae type B according to the original ratio will form a competitive relationship and affect the haemophilus of type B influenza The normal conjugation process of bacillus capsular saccharide, therefore can't realize this technical scheme.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
separationaaaaaaaaaa
separationaaaaaaaaaa
Login to View More

Abstract

The invention provides a polyvalent pneumococcus and B-type haemophilus influenzae combined vaccine. Each dose of the combined vaccine contains 50-500 micrograms / ml and 10-60 micrograms / ml of B-type haemophilus influenzae capsule polysaccharide, and the serotype of pneumococcus is one or more of 1A, 3A, 4A, 5A, 6A, 6B, 7F, 8N, 9N, 9V, 12F, 14B, 15B, 18C, 19A, 19F, 22F and 23F. Compared with the prior art, the combined vaccine is safe, reliable and good in stability, and the application prospect of the combined vaccine is very wide.

Description

technical field [0001] The invention relates to a vaccine, in particular to a combined vaccine, especially a multivalent pneumococcus-Haemophilus influenzae type B combined vaccine. Background technique [0002] 1. Bacterial pneumonia [0003] Bacterial pneumonia (BP) is the most common pneumonia and one of the most common infectious diseases. There are many types of pathogenic bacteria that cause BP, such as Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa, etc., which pose a great threat to the health of children and the elderly. The diagnosis of such diseases mainly relies on medical history and imaging examinations. Isolation and culture of pathogens can help to know the choice of antibiotics, but it is not timely enough. [0004] Generally speaking, BP patients usually present symptoms such as cough, expectoration, fever, chills, and chest pain. In most cases of pneumonia, characteristic changes su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/116A61K39/09A61K39/102A61K9/19A61K47/26A61P31/04
CPCA61K9/19A61K39/09A61K39/102A61K47/26A61K2039/6037A61K2039/6068A61K2039/70
Inventor 吴克艾智武刘昊智袁军
Owner BRAVOVAX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com